JP4133829B2 - 人参の加工方法 - Google Patents
人参の加工方法 Download PDFInfo
- Publication number
- JP4133829B2 JP4133829B2 JP2003557302A JP2003557302A JP4133829B2 JP 4133829 B2 JP4133829 B2 JP 4133829B2 JP 2003557302 A JP2003557302 A JP 2003557302A JP 2003557302 A JP2003557302 A JP 2003557302A JP 4133829 B2 JP4133829 B2 JP 4133829B2
- Authority
- JP
- Japan
- Prior art keywords
- ginseng
- extract
- water
- processed
- carrot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 244000000626 Daucus carota Species 0.000 title claims description 34
- 235000002767 Daucus carota Nutrition 0.000 title claims description 34
- 238000003672 processing method Methods 0.000 title claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 89
- 241000208340 Araliaceae Species 0.000 claims description 83
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 83
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 83
- 235000008434 ginseng Nutrition 0.000 claims description 83
- 239000000284 extract Substances 0.000 claims description 80
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- 235000002789 Panax ginseng Nutrition 0.000 claims description 22
- 238000010438 heat treatment Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 229930182494 ginsenoside Natural products 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229940089161 ginsenoside Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 4
- 241001527087 Panax vietnamensis Species 0.000 claims description 3
- 235000017726 Panax vietnamensis Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 241000951471 Citrus junos Species 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229930182490 saponin Natural products 0.000 description 52
- 235000017709 saponins Nutrition 0.000 description 52
- 235000020710 ginseng extract Nutrition 0.000 description 50
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 50
- 150000007949 saponins Chemical class 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 230000000052 comparative effect Effects 0.000 description 39
- 229940008396 carrot extract Drugs 0.000 description 31
- 230000000694 effects Effects 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 19
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 17
- 244000060011 Cocos nucifera Species 0.000 description 15
- 235000013162 Cocos nucifera Nutrition 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000002021 butanolic extract Substances 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 230000006872 improvement Effects 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 208000010228 Erectile Dysfunction Diseases 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- 201000001881 impotence Diseases 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000007721 medicinal effect Effects 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 7
- 241000220225 Malus Species 0.000 description 7
- 235000011430 Malus pumila Nutrition 0.000 description 7
- 235000015103 Malus silvestris Nutrition 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000003925 brain function Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000003792 cranial nerve Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000006049 herbal material Substances 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- NJUXRKMKOFXMRX-RNCAKNGISA-N Ginsenoside Rg5 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(/C)=C/CC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NJUXRKMKOFXMRX-RNCAKNGISA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000002034 butanolic fraction Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- NJUXRKMKOFXMRX-AXUZFSSLSA-N ginsenoside Rg5 Natural products CC(=CCC=C(C)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]3[C@@]4(C)CC[C@@H](O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@@H]4CC[C@@]23C)C NJUXRKMKOFXMRX-AXUZFSSLSA-N 0.000 description 2
- NJUXRKMKOFXMRX-UHFFFAOYSA-N ginsenoside Rz1 Natural products CC(C)=CCC=C(C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NJUXRKMKOFXMRX-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- -1 protopanaxadiol saponins Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019614 sour taste Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000001196 vasorelaxation Effects 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- KWDWBAISZWOAHD-MHOSXIPRSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]o Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4C(=C)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KWDWBAISZWOAHD-MHOSXIPRSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 description 1
- KWDWBAISZWOAHD-UHFFFAOYSA-N Ginsenoside Rk1 Natural products CC(C)=CCCC(=C)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O KWDWBAISZWOAHD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 244000081841 Malus domestica Species 0.000 description 1
- 244000230712 Narcissus tazetta Species 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
Description
J. Nat. Prod. 63, 1702(2000) Biol. Pharm. Bull. 21, 79(1998), Korean J. Ginseng Sci. 21, 132(1997) J. Neuroscience Res. 53, 426(1998), Neuro Report 9, 226(1998) Jpn. J. cancer Res. 87, 357(1996), J. cancer Res. Clin. Oncol. 120, 24(1993), Anticancer Res. 17, 1067(1997), Cancer Letters 150, 41(2000), Dietary Anticarcinogenesis and Antimutagenesis 274(2000) J. Natural Products 63, 1702, 2000
白参2.5Kgと五味子1.5Kgに水40lを入れて加圧抽出装置で4時間加熱し煮た後(内部温度120℃)、水20lを蒸留して除去し、エタノール48lを入れて2時間加熱して抽出し、室温に冷却した後濾過した(1次濾液)。残渣に水16lとエタノール48lを入れて3時間加熱抽出し冷却して濾過した濾液と1次濾液とを合わせて、抽出物の容量が1/3になるまで濃縮して噴霧乾燥し、加工人参抽出物を得た。
白参2.5Kgと山査子1.5Kgを前記実施例1と同様に処理して加工人参抽出物を得た。
尾参50gと五味子30gに水700mlを入れて4時間加熱して煮た後、室温に冷却して濾過し、濾液を減圧濃縮して加工人参抽出物を得た。
紅参20gと五味子15gに水300mlを入れて3時間煮た後、室温に冷却して濾過し、濾液を減圧濃縮して加工人参抽出物を得た。
尾参25gを細切りにして山査子20gと混合し、水200mlを入れて4時間加熱して煮た後、室温に冷却して濾過し、濾液を減圧濃縮して加工人参抽出物を得た。
白参20gと木瓜25gに水400mlを入れて、前記実施例3と同様に処理して加工人参抽出物を製造した。
白参20gと梅実果肉乾燥品15gに水300mlを入れて、前記実施例3と同様に処理して加工人参抽出物を製造した。
白参15gと柚子の果肉15gに水200mlを入れて、前記実施例3と同様に処理して加工人参抽出物を製造した。
紅参15gと枳実20gに水300mlを入れて、前記実施例3と同様に処理して加工人参抽出物を製造した。
花旗参20gと山茱萸20g、竹節人参20gと山査子20g、三七人参15g、乾燥した人参葉20gと五味子15gに水350mlを各々入れて、4時間加熱して煮た後、水を蒸留して除去し、エタノール400mlを入れて2時間加熱還流させて、室温に冷却して濾過し、濾液を減圧濃縮して加工人参抽出物を製造した。
白参10gと山査子10gに水200mlを入れて1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
白参10gと五味子10gに水200mlを入れて1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
白参10gと山茱萸10gに水200mlを入れて1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却して濾過し加工人参抽出物を得た。
白参10gと木瓜10gに水200mlを入れて1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
白参10gと梅実果肉10gに水200mlを入れて1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
白参10gと柚子果肉10gに水200mlを入れて1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
白参10gと枳実10gに水200mlを入れて1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
紅参10gと五味子10gに水200mlを入れて1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
前記実施例1から得た加工人参抽出物50gを水350mlに溶かして、ジクロロメタン350mlずつを使用し2回抽出して、水層を水飽和ブタノール350mlずつを使用して3回抽出し合わせて、水350mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例2から得た加工人参抽出物50gを水350mlに溶かして、ジクロロメタン350mlずつを使用し2回抽出して、水層を水飽和ブタノール350mlずつを使用して3回抽出し合わせて、水350mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例11から得た加工人参抽出物5.1gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例12から得た加工人参抽出物5.4gを水50mlに溶かして、ジクロロメタンを50mlずつ使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例13から得た加工人参抽出物5gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例14から得た加工人参抽出物5.5gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例15から得た加工人参抽出物4.8gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例16から得た加工人参抽出物4.9gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例17から得た加工人参抽出物5.1gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記実施例18から得た加工人参抽出物5.2gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
白参15g、山査子5g及び五味子5gに水200mlを入れて5時間加熱して煮た後、室温に冷却して濾過し、濾液を減圧濃縮して加工人参抽出物を得た。
白参15g、五味子3g、山査子3g及び山茱萸4gに水250mlを入れて5時間加熱して煮た後、室温に冷却して濾過し、濾液を減圧濃縮して加工人参抽出物を得た。
前記実施例1で製造した加工人参抽出物粉末500gと結晶性セルロース196g、ステアリン酸マグネシウム4gをよく混合し、通常の方法により打錠して700mg錠剤を製造した。
前記実施例2で製造した加工人参抽出物500g、結晶性セルロース196g、ステアリン酸マグネシウム4gをよく混合し、通常の方法により打錠して700mg錠剤を製造した。
前記実施例1で製造した加工人参抽出物粉末100g、結晶性セルロース95g、酸化ケイ素5gをよく混合し、通常の方法により400mg硬質カプセル剤を製造した。
前記実施例1で製造した加工人参抽出物粉末200g、大豆油280g、レシチン15g、黄蝋5gを均質に混合し、通常の方法により500mg軟質カプセル剤を製造した。
前記実施例2で製造した加工人参抽出物500g、とうもろこし澱粉196g、ステアリン酸マグネシウム4gをよく混合し、通常の方法により顆粒剤を製造した。
前記実施例2で製造した加工人参抽出物300g、とうもろこし澱粉100g、結晶性セルロース50g、蜂蜜150gをよく混合し、通常の方法により100mg丸剤を製造した。
前記実施例1で製造した加工人参抽出物100g、紅参抽出物濃縮液(人参サポニン140mg/g)20g、冬虫夏草抽出物粉末(2.5:1に濃縮したもの)100g、ナツメ濃縮液(55ブリックス)50g、ビタミンB1塩酸塩2g、ビタミンB2 1g、ビタミンB6塩酸塩2g及び砂糖200gに精製水を加え溶解させて、2lの液剤を製造した。
前記実施例1で製造した加工人参抽出物10g、クエン酸1g、アラビアゴム1g及び砂糖5gを水に希釈して通常の方法により飲料を製造するが、95℃で15秒間殺菌、冷却して、総100mlのドリンクタイプの飲料製品を製造した。
紅参2Kg、白参5Kg、五味子5Kg、山査子5Kgを各々別途に、前記実施例3と同様に行って抽出物粉末を製造した。
白参10gに水200mlを加え1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
紅参10gに水200mlを加え1時間加熱して煮た後水100mlを蒸発させて、蓋をして3時間加熱した後、水を蒸発させて除去した。これにメタノール400mlを加え1時間加熱抽出して、冷却し濾過して加工人参抽出物を得た。
前記比較例2から得た加工人参抽出物3.4gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
前記比較例3から得た加工人参抽出物3.4gを水50mlに溶かして、ジクロロメタン50mlずつを使用し2回抽出して、水層を水飽和ブタノール50mlずつを使用して3回抽出し合わせて、水50mlで洗滌した後、ブタノール抽出液を減圧濃縮して人参サポニン分画抽出物を得た。
40mlステンレス容器に白参5gと水5mlを加えた後、加圧滅菌器に入れて密閉し120℃で2時間加熱した。加熱の終わった加工人参5gを取って、メタノール100mlずつを使用し3回抽出して濃縮させた後水に懸濁させて、エーテル100mlずつを使用し3回抽出した。残りの水層をブタノール100mlずつを使用し3回抽出した後、ブタノール分画を濃縮させて人参サポニン分画抽出物を得た。
40mlステンレス容器に白参5gと水5mlを加えた後、加圧滅菌器に入れて密閉し130℃で2時間加熱した。加熱の終わった加工人参5gを取って、メタノール100mlずつを使用し3回抽出して濃縮させた後水に懸濁させて、エーテル100mlずつを使用し3回抽出した。残りの水層をブタノール100mlずつを使用し3回抽出した後、ブタノール分画を濃縮させて人参サポニン分画抽出物を得た。
紅参5gをメタノール100mlずつを使用し3回、3時間加熱抽出して濃縮した後水100mlに懸濁させて、エーテル100mlずつを使用し3回抽出した。水層をブタノール100mlずつを使用し3回抽出して合わせた後、濃縮させて紅参サポニン分画抽出物を得た。
前記比較例1で製造した白参抽出物350g、五味子抽出物210g、結晶性セルロース136g及びステアリン酸マグネシウム4gをよく混合し、通常の方法により打錠して700mg錠剤を製造した。
前記比較例1で製造した白参抽出物350g、山査子抽出物210g、結晶性セルロース136g及びステアリン酸マグネシウム4gをよく混合し、通常の方法により打錠して700mg錠剤を製造した。
前記比較例1で製造した紅参抽出物350g、結晶性セルロース246g、とうもろこし澱粉100g及びステアリン酸マグネシウム4gをよく混合し、通常の方法により打錠して700mg錠剤を製造した。
前記実施例21〜28及び比較例4〜5から得たサポニン分画抽出物を薄層クロマトグラフィー法により分析した(展開溶媒;クロロホルム:メタノール:水=15:10:2.5、発色剤;10%硫酸を噴霧した後加熱)[図1及び図2]。また、高速液体クロマトグラフィー(HPLC)はCapcell pak MG C18(4.6×250 mm)、検出203nm、溶出溶媒は、(A)10%アセトニトリル/水、(B)90%アセトニトリル/水を時間帯別に比率を異にして実施し、その結果を図3に示した。
勃起不全症を有している45〜60歳の男性40名を8名ずつ5群に分けて、前記参考実施例1、参考実施例2、参考比較例1、参考比較例2及び参考比較例3で製造した錠剤を1回2錠ずつ一日3回、30日間服用させて、勃起不全症改善効果を自覚症状と問診により評価して、その結果を次の表2に示した。
軽微な神経障害を有している49〜60歳の男性糖尿病患者40名を、8名ずつ5群に分けて、前記参考実施例1、参考実施例2、参考比較例1及び参考比較例2で製造した錠剤を6錠ずつ服用させて、服用前、服用後45分、服用後90分にLaser Doppler Flowmetry装置を用いて患者らの右足に対し血流を測定した。偽薬群は同じ量のとうもろこし澱粉で製造した錠剤を服用させた。その結果を次の表3に示した。
体重260〜280gのSprague-Dawley系ラットの胸部大動脈を摘出して、内皮細胞を損傷させないようにして2〜3mmの長さの大動脈環を用意した。クレブス炭酸緩衝液(Krebs’ bicarbonate buffer;mM: NaCl 118,KCl 4.7,CaCl2 2.5,NaHCO3 25,MgSO4 1.2,KH2PO4 1.2, ブドウ糖11.0,95% O2+5% CO2,37 ℃)20mlが入っている臓器チャンバーに懸垂して等尺性張力の記録装置に連結した。大動脈環を2g休止張力で60分間平衡させた。フェニレフリン30μMを加え安定した収縮が現れたことを確認して、アセチルコリン1μMを加え内皮細胞が存在することを確認した。大動脈環を45分間3回洗滌して、再びフェニレフリンで収縮させて、試料を累積的に加えて血管弛緩作用を観測した[図4]。使用した試料は、前記実施例21、実施例22及び比較例4から得たサポニン分画抽出物を使用した。
45〜60歳の男性高血圧患者21名を11名、10名の2群に分けて、一群には前記参考実施例2で製造した錠剤を、他群には前記参考比較例2で製造した錠剤を、一日3回、1回2錠ずつ30日間服用させて、血圧の変化を測定して次の表4に示した。
健康な男性の上膊静脈から採血して(抗凝固剤は15% citric aicd‐citrate‐dextroseを使用)、120gで15分間遠心分離し得られた血小板の豊富な血漿を、500gで10分間遠心分離して血小板を得た。2億個血小板/mlに懸濁させてwashed plateletを得た。文献[高麗人参学会誌 21, 132(1997)]に記載の方法により、コラーゲンにより誘導される血小板凝集反応に対しての加工人参抽出物の効果を測定して、次の表5に示した。
抗癌剤であるシスプラチンの投与により発生する副作用の中で、腎臓機能阻害に対しての本発明による加工人参のサポニン分画抽出物の効果を測定した。体重200g前後のSprag Dowry系ラットを6匹ずつ五個群に分けて、対照群(食塩水投与)を除いた全ての群にシスプラチン5mg/kg/5ml溶液を腹腔投与した。前記実施例22から得たサポニン分画抽出物300mg/kg、比較例4から得たサポニン分画抽出物300mg/kgを、各々シスプラチン投与72、48、24、12時間前に腹腔投与して(事前投与群)、シスプラチン投与12、24、48、72時間後に腹腔投与した(事後投与群)。四日目に実験動物から血液を採取して血清を製造した。
脳卒中の治療及び予防に対しての効果を調べるために、脳細胞がグルタメート過多露出により死滅することに対する加工人参サポニン分画抽出物の効果を文献[J. Neurosci. Res. 53, 426 (1998)]に基づいて測定し、次の表7に示した。
仔牛血清培養液に人間癌細胞株を接種し48時間培養した後、96−ウェル培養容器で一日間継代培養した。その後、加工人参抽出物を処理して48時間後MTT溶液を加え不溶性ホルマジンを生成させた。遠心分離後、沈殿層にジメチルスルホキシドを加えホルマジン沈殿を溶解させて、570nmで吸光度を自動平板読取り機(automatic flat reader)により測定し50%細胞が生存する濃度を算出して、その結果を次の表8に示した。
記憶力障害症状を有する61〜74歳の老人20名(男性10名、女性10名)を男女各々五人ずつ二つの群に分けて、実施例2、参考実施例2で製造した錠剤を一日2回、1回2錠ずつ3ヶ月間服用させて、問診により記憶力障害症状の改善程度を観察して、その結果を次の表9に示した。
本発明による加工人参抽出物に対して毒性実験を次のように行った。具体的に前記実施例1、実施例2の加工人参抽出物を0.2%ツイーン80水溶液に溶かして、これを体重20gのICR系マウス(群当り20匹)に各々5g/kgずつ経口投与して7日間観察したが、死亡したマウスはいなかった。
Claims (3)
- 人参を主材として加熱抽出する人参の加工方法において、
1)人参100重量%と、五味子、山査子 、山茱萸 、木瓜、梅実、柚子 、枳実、りんご、石榴及びオレンジの中から選ばれた1種または2種以上の混合物10〜1000重量%とに、4〜10倍量の水を加えて沸点で1〜6時間加熱する段階;
2)室温に冷却した後、濾過する段階;及び
3)濾液を濃縮させてエキスや粉末に製造する段階;
を含み、前記で製造されたエキスや粉末中のジンセノサイド (Rg3 + Rg5)/(Rb1 + Rb2 + Rc + Rd) の比率が10〜45であることを特徴する、人参の加工方法。 - 前記1)段階の後、水を蒸発させてエタノールまたはメタノールで1〜3時間加熱抽出する段階を追加に行うことを特徴とする、請求項1に記載の人参の加工方法。
- 前記人参は、白参、水参、尾参、紅参、人参葉、花旗参、田七人参または竹節人参であることを特徴とする、請求項1または2に記載の人参の加工方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0000572A KR100425022B1 (ko) | 2002-01-05 | 2002-01-05 | 가공인삼 추출물 및 이를 함유하는 약제 조성물 |
PCT/KR2003/000003 WO2003056929A1 (en) | 2002-01-05 | 2003-01-02 | Method for processing ginseng and the uses of extract of processed ginseng |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006502082A JP2006502082A (ja) | 2006-01-19 |
JP4133829B2 true JP4133829B2 (ja) | 2008-08-13 |
Family
ID=19718200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003557302A Expired - Lifetime JP4133829B2 (ja) | 2002-01-05 | 2003-01-02 | 人参の加工方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7585525B2 (ja) |
EP (1) | EP1467627B1 (ja) |
JP (1) | JP4133829B2 (ja) |
KR (1) | KR100425022B1 (ja) |
CN (1) | CN100450495C (ja) |
AU (1) | AU2003202144B2 (ja) |
CA (1) | CA2470402A1 (ja) |
HK (1) | HK1069508A1 (ja) |
WO (1) | WO2003056929A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09173396A (ja) * | 1995-12-27 | 1997-07-08 | Masashi Kondo | 骨壷及びその製作方法 |
US7910194B2 (en) | 1997-02-28 | 2011-03-22 | Columbia Insurance Company | Homogenously branched ethylene polymer carpet backsizing compositions |
US8283017B2 (en) | 1997-02-28 | 2012-10-09 | Columbia Insurance Company | Carpet, carpet backings and methods |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100497665B1 (ko) * | 2002-03-28 | 2005-07-01 | 주식회사 진생사이언스 | 가공인삼 추출물 함유 피부질환 치료제 조성물 |
AU2003252564A1 (en) * | 2003-08-18 | 2005-03-07 | Yuyu Inc. | A ginseng preparation using vinegar and process for thereof |
WO2005034963A1 (en) * | 2003-10-15 | 2005-04-21 | Panagin Pharmaceuticals Inc. | USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER |
KR100656888B1 (ko) * | 2004-06-10 | 2006-12-13 | 건국대학교 산학협력단 | 뇌 선조체 병소 유발물질로부터 뇌 선조체 보호효과를 갖는 진세노사이드 함유 조성물 |
KR100557779B1 (ko) * | 2004-06-11 | 2006-03-07 | 주식회사 유니젠 | 집중력 및 기억력 저하의 예방 또는 개선을 위한 인삼조성물 |
WO2006115307A1 (en) * | 2005-04-26 | 2006-11-02 | Ko, Boong-Kyung | Method of extracting ginsengnoside rg2m, pharmaceutical composition including ginsengnoside rg2, and uses thereof |
MX2008001044A (es) * | 2005-08-01 | 2008-03-19 | Cadbury Adams Usa Llc | Contenedor que combina un producto consumible secundario y una bebida. |
KR100802149B1 (ko) * | 2005-09-16 | 2008-02-11 | 주식회사 진생사이언스 | 혈관 손상에 의한 질환 예방 및 치료용 조성물 |
CN100378117C (zh) * | 2006-03-17 | 2008-04-02 | 中国科学院长春应用化学研究所 | 一种从人参根中获得二醇型人参皂苷f2含量较高的人参皂苷粗提物的方法 |
US20100168406A1 (en) * | 2006-03-21 | 2010-07-01 | Zaixi Cai | USE OF GINSENOSIDE Rb2 MONOMER IN THE MANUFACTURE OF MEDICAMENTS FOR THROMBOLYSIS |
CN1899352B (zh) * | 2006-07-20 | 2010-05-12 | 罗益民 | 一种益气复脉的中药有效部位组合物 |
KR100840764B1 (ko) * | 2007-10-01 | 2008-06-23 | 주식회사 진생사이언스 | 혈관 손상에 의한 질환의 예방 및 개선용 건강기능식품 |
JP2009120518A (ja) * | 2007-11-13 | 2009-06-04 | Wako Kagaku Kk | 田七人参抽出物 |
AU2009216012A1 (en) * | 2008-02-19 | 2009-08-27 | Unigen, Inc. | Leaves extract of panax SP., a process of making the same and uses thereof |
KR101144059B1 (ko) * | 2008-07-30 | 2012-05-23 | 고려대학교 산학협력단 | 석류 추출물 및 홍삼 추출물을 포함하는 당뇨병 또는비만의 예방 또는 치료용 조성물 |
US9956241B2 (en) | 2009-05-04 | 2018-05-01 | Naturex, S.A. | Application of American Ginseng to enhance neurocognitive function |
US20100278944A1 (en) * | 2009-05-04 | 2010-11-04 | Naturex, S.A. | Application of american ginseng to enhance neurocognitive function |
KR101593618B1 (ko) | 2009-05-26 | 2016-02-15 | (주)아모레퍼시픽 | 사포닌의 생체 이용률 증진 조성물 |
KR100992800B1 (ko) * | 2010-05-14 | 2010-11-08 | 주식회사 지씨에이치앤피 | 미량의 진세노사이드 성분이 증가된 신규한 가공인삼 또는 가공인삼추출물의 제조방법 |
CN103237556B (zh) * | 2010-10-04 | 2016-03-16 | 韩国韩医学研究院 | 包含乌梅提取物的用于预防或治疗痴呆的组合物 |
KR101274605B1 (ko) * | 2011-06-01 | 2013-06-13 | 강원대학교산학협력단 | 향기성이 증진된 것을 특징으로 하는 더덕추출물 |
CN102435697B (zh) * | 2011-09-07 | 2014-02-05 | 吉林天药本草堂制药有限公司 | 心舒胶囊中人参皂苷Rg1和Rb1含量的测定方法 |
KR101260047B1 (ko) * | 2012-05-25 | 2013-05-06 | 한국과학기술연구원 | 마이크로웨이브 조사에 의해 진세노사이드 알지3, 알지5 및 알케이1의 함량비율이 증가된 파낙스속 식물 추출물, 그 제조방법, 및 그 가공 파낙스속 식물 추출물을 포함하는 조성물 |
KR101409168B1 (ko) * | 2012-06-25 | 2014-06-20 | 순천대학교 산학협력단 | 기능성분강화 홍삼추출액 제조방법 및 그 조성물 |
CN103125941A (zh) * | 2013-03-22 | 2013-06-05 | 金万洙 | 五味子发酵物制品、五味子人参发酵物制品及其应用 |
CN103230450A (zh) * | 2013-04-08 | 2013-08-07 | 张宗升 | 一种中药组合物及其制备方法 |
EP3040078B1 (en) * | 2013-08-30 | 2021-02-24 | Green Cross Wellbeing Corporation | Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent |
WO2015159922A1 (ja) * | 2014-04-16 | 2015-10-22 | 花王株式会社 | ニンジン抽出物の製造方法 |
CN104383140A (zh) * | 2014-10-24 | 2015-03-04 | 许炎武 | 治疗头皮下血肿的药物组合物 |
KR102084260B1 (ko) * | 2017-02-27 | 2020-03-03 | 국가식품클러스터지원센터 | 팽화 인삼 및 과일 엑기스를 포함하는 인삼 음료 |
CN107125747A (zh) * | 2017-07-11 | 2017-09-05 | 安徽智联管理咨询有限公司 | 西洋参乌梅营养粉的加工方法 |
KR101979351B1 (ko) | 2017-12-28 | 2019-05-17 | 재단법인 진안홍삼연구소 | 인삼 츄잉정 및 그 제조방법 |
CN109134580B (zh) * | 2018-11-15 | 2020-10-30 | 吉林大学 | 一种从人参叶中提取纯化vinaginsenoside R15的方法 |
CN109613165A (zh) * | 2018-11-26 | 2019-04-12 | 江西省药明扬海医药科技有限公司 | 一种金水宝金胶囊定性检测方法 |
CN109874893A (zh) * | 2019-04-19 | 2019-06-14 | 吉林大学 | 一种人参叶绿茶饮料及其生产方法 |
CN110680822A (zh) * | 2019-11-15 | 2020-01-14 | 邹澄 | 一种人参二醇、人参三醇的pcc氧化产物的应用 |
KR102436041B1 (ko) | 2020-05-19 | 2022-08-26 | 주식회사 동진제약 | 생약재 미네랄 효모 발효액을 이용하여 제조되는 발효 홍삼 조성물 및 그 제조방법 |
KR102436045B1 (ko) | 2020-05-19 | 2022-08-26 | 주식회사 동진제약 | 생약재 미네랄 효모 발효액을 이용하여 제조되는 발효 흑삼 조성물 및 그 제조방법 |
CN112690451A (zh) * | 2020-12-24 | 2021-04-23 | 孙立伟 | 人参醇提物在促睡眠的保健品或者食品中的应用 |
CN113813310B (zh) * | 2021-11-22 | 2022-03-04 | 广东众尔健生物科技有限公司 | 一种防治脑部疾病的中药组合物及其制备方法和应用 |
KR102505329B1 (ko) * | 2022-10-17 | 2023-03-07 | 대동고려삼 주식회사 | 인지기능 개선 효과가 있는 소재를 이용한 홍삼 가공식품의 제조방법 |
CN116617335A (zh) * | 2023-01-17 | 2023-08-22 | 中国中医科学院西苑医院 | 一种防治血管老化的中药复方组合物、制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59118053A (ja) * | 1982-12-24 | 1984-07-07 | Hayashibara Biochem Lab Inc | 飲食物とその製造方法 |
JPS61194031A (ja) * | 1985-02-22 | 1986-08-28 | Kanebo Ltd | 制癌作用増強剤 |
JP3160313B2 (ja) * | 1991-07-01 | 2001-04-25 | 勲 北川 | 制癌剤 |
WO1996040181A1 (en) * | 1995-06-07 | 1996-12-19 | Cheil Je Dang Co. | Processed ginseng having enhanced pharmacological effect |
KR100192678B1 (ko) * | 1995-06-07 | 1999-06-15 | 손경식 | 약효가 증강된 가공인삼 제품 |
WO1997018824A1 (en) * | 1995-11-22 | 1997-05-29 | Cheil Je Dang Co. | Vasodilating composition |
KR100217923B1 (ko) * | 1996-01-18 | 1999-09-01 | 이상준 | 인삼 가공방법 및 그 방법에 의해 제조되는 가공 인삼 |
KR0185539B1 (ko) * | 1996-12-05 | 1999-05-01 | 김춘란 | 종합기침약 및 그의 제조방법 |
US6083932A (en) | 1997-04-18 | 2000-07-04 | Cv Technologies Inc. | Pharmaceutical compositions derived from ginseng and methods of treatment using same |
KR100239879B1 (ko) * | 1997-11-05 | 2000-02-01 | 김상조 | 간암 예방 및 치료용 생약제 |
KR100382564B1 (ko) * | 1998-05-14 | 2003-07-16 | 김기영 | 치매병 예방 및 치료용 생약조성물 |
KR20020008726A (ko) * | 2000-07-25 | 2002-01-31 | 유종근 | 원기를 보하는 한방 건강음료 원기생 및 그의 제조방법 |
CN1156289C (zh) * | 2001-02-21 | 2004-07-07 | 灵素(北京)药业有限公司 | 西洋参提取物的制造工艺 |
-
2002
- 2002-01-05 KR KR10-2002-0000572A patent/KR100425022B1/ko active IP Right Grant
-
2003
- 2003-01-02 AU AU2003202144A patent/AU2003202144B2/en not_active Ceased
- 2003-01-02 JP JP2003557302A patent/JP4133829B2/ja not_active Expired - Lifetime
- 2003-01-02 CN CNB038008114A patent/CN100450495C/zh not_active Expired - Fee Related
- 2003-01-02 CA CA002470402A patent/CA2470402A1/en not_active Abandoned
- 2003-01-02 EP EP03701150.9A patent/EP1467627B1/en not_active Expired - Lifetime
- 2003-01-02 US US10/482,782 patent/US7585525B2/en not_active Expired - Lifetime
- 2003-01-02 WO PCT/KR2003/000003 patent/WO2003056929A1/en active IP Right Grant
-
2005
- 2005-03-11 HK HK05102144.6A patent/HK1069508A1/xx not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09173396A (ja) * | 1995-12-27 | 1997-07-08 | Masashi Kondo | 骨壷及びその製作方法 |
US7910194B2 (en) | 1997-02-28 | 2011-03-22 | Columbia Insurance Company | Homogenously branched ethylene polymer carpet backsizing compositions |
US8283017B2 (en) | 1997-02-28 | 2012-10-09 | Columbia Insurance Company | Carpet, carpet backings and methods |
Also Published As
Publication number | Publication date |
---|---|
JP2006502082A (ja) | 2006-01-19 |
EP1467627A4 (en) | 2006-03-15 |
KR20030059984A (ko) | 2003-07-12 |
KR100425022B1 (ko) | 2004-03-27 |
WO2003056929A8 (en) | 2004-05-27 |
AU2003202144A1 (en) | 2003-07-24 |
CA2470402A1 (en) | 2003-07-17 |
US7585525B2 (en) | 2009-09-08 |
HK1069508A1 (en) | 2005-05-27 |
EP1467627A1 (en) | 2004-10-20 |
CN1545382A (zh) | 2004-11-10 |
US20050031711A1 (en) | 2005-02-10 |
CN100450495C (zh) | 2009-01-14 |
AU2003202144B2 (en) | 2006-03-16 |
WO2003056929A1 (en) | 2003-07-17 |
EP1467627B1 (en) | 2016-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4133829B2 (ja) | 人参の加工方法 | |
RU2294208C2 (ru) | Применение экстракта обработанного женьшеня и выделенных из него сапонинов | |
JP4777776B2 (ja) | 酢を利用した人参製剤及びこれの製造方法 | |
JP6053873B2 (ja) | サポニンの生体利用率増進組成物 | |
US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
RU2358749C1 (ru) | Способ получения обработанного женьшеня с повышенным количеством гинзенозида rg5 | |
CN101543295B (zh) | 一种降压降脂保健茶 | |
KR100471340B1 (ko) | 인삼의 가공방법 | |
JP2018506524A (ja) | バーンアウト症候群の予防、改善、または治療用組成物 | |
KR101910013B1 (ko) | 한약재 추출물(socg)을 함유하는 통증의 개선, 예방 또는 치료용 조성물 | |
KR101987554B1 (ko) | 새싹보리의 풋내와 누에가루 및 꾸지뽕의 불쾌취를 제거한 항산화 또는 혈당강하 활성성분 함량이 증가된 새싹보리, 누에가루 및 꾸지뽕잎 혼합차 제조방법 | |
CN1381236A (zh) | 一种含野黄芩甙和咖啡酰奎宁酸的药用组合物 | |
KR20170109703A (ko) | 혼합 생약 추출물의 분획물을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
KR100453542B1 (ko) | 가공인삼 추출물을 함유하는 식품첨가제 및 건강식품 | |
KR100979882B1 (ko) | 금은화 추출물과 홍삼 추출물을 함유하는 당뇨병 예방 및치료용 조성물 | |
KR20140108104A (ko) | 한인진 및 울금의 복합추출물을 유효성분으로 포함하는 비만 관련 질환의 예방, 억제 또는 치료용 조성물 | |
KR20040020693A (ko) | 효능이 증강된 인삼추출물의 제조 방법 | |
CN1119114A (zh) | 沙棘黄酮口服液及其制备 | |
KR101367885B1 (ko) | 인삼 및 비티스속 식물의 조합 추출물을 유효성분으로 함유하는 기억력 증진, 학습능력 향상, 퇴행성 뇌질환의 치료 및 예방용 조성물 | |
AU2002356431A1 (en) | Herbal preparation for management of cardiovascular and neurologic disorders | |
KR20060014006A (ko) | △20-진세노사이드의 함량이 높은 인삼추출물의 가공방법및 가공인삼 추출물의 용도 | |
WO2013133677A1 (ko) | 홍삼 추출물의 감식초 반응 혼합물을 함유한 혈관 질환의 예방 또는 치료용 조성물 | |
JP2004091349A (ja) | 感染性疾患予防用及び/又は治療用組成物 | |
CN111567804A (zh) | 茉莉花咀嚼片及其制备方法 | |
KR20190142674A (ko) | 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080318 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080401 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080507 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080602 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110606 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4133829 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110606 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120606 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120606 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130606 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |